1.5 Percent Ruxolitinib Cream Safe, Effective for Teens With Eczema
By Lori Solomon HealthDay Reporter
FRIDAY, May 31, 2024 -- Long-term intermittent use of ruxolitinib cream is well tolerated and provides disease control in adolescent patients with atopic dermatitis (AD), according to a study published online May 2 in the American Journal of Clinical Dermatology.
Lawrence F. Eichenfield, M.D., from the University of California San Diego, and colleagues assessed the safety and efficacy of 1.5 percent ruxolitinib cream versus vehicle and long-term disease control of ruxolitinib cream among adolescents using pooled data from phase 3 studies. The analysis included 245 adolescents (aged 12 to 17 years) with AD for at least two years.
The researchers found that at week 8, substantially more patients who applied 1.5 percent ruxolitinib cream versus vehicle achieved Investigator's Global Assessment (IGA) treatment success (50.6 versus 14.0 percent), ≥75 percent improvement in the Eczema Area and Severity Index (60.9 versus 34.9 percent), and a 4-point improvement or greater in the itch numerical rating scale (52.1 versus 17.4 percent). During the long-term safety period, mean trough steady-state ruxolitinib plasma concentrations at weeks 12 and 52 were 27.2 and 15.5 nM, respectively. With ruxolitinib, the percentage of patients achieving an IGA score of 0 or 1 was sustained or further increased. Application site reactions through 52 weeks occurred in 1.8 percent of participants applying 1.5 percent ruxolitinib cream at any time. No patients reported serious adverse events.
"Treatment with 1.5 percent ruxolitinib cream in adolescent patients with mild-to-moderate atopic dermatitis had anti-inflammatory and antipruritic effects comparable with those observed in the overall study population," the authors write.
The study was funded by Incyte, the manufacturer of ruxolitinib.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted May 2024
Read this next
Lebrikizumab Tied to Sustained Atopic Dermatitis Treatment Effect
TUESDAY, June 18, 2024 -- Lebrikizumab is associated with sustained effects for moderate-to-severe atopic dermatitis for up to week 52 following withdrawal of treatment, according...
Parental E-Cigarette Use Linked to Increase in Pediatric Atopic Dermatitis
TUESDAY, May 28, 2024 -- Parental electronic cigarette use is associated with increased odds of pediatric atopic dermatitis (AD), according to a research letter published online...
Stigma Affects Quality of Life in Children With Chronic Skin Conditions
TUESDAY, April 30, 2024 -- Health care professionals should consider stigmatization and bullying in assessing the social and mental health of children and adolescents with chronic...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.